GlaxoSmithKline has made a deal for Luke Miels to start as its head of pharmaceuticals in September, following a dispute over his contract with AstraZeneca.
Miels was poached by GSK in January but was unable to officially join after AstraZeneca filed a lawsuit. The agreement avoids the need for a court case over the contract.
GSK was planning for Miels to work alongside outgoing pharma head Abbas Hussain, but this dispute has made that reality impossible.
Miels brings both commercial and scientific experience after working at AstraZeneca, Roche and Sanofi.
Read the Reuters report